Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and pre-clinical data without primary clinical trial data
PubMed 36736539 · doi:10.1016/j.peptides.2023.170962
What was done
This narrative review summarizes existing preclinical and clinical literature on glucagon receptor (GCGR) multi-agonists (combining GCGR, GLP-1R, and GIPR) for obesity and metabolic disease, examining how glucagon stimulates energy expenditure and alters amino acid metabolism.
What was found
No quantitative findings, effect sizes, or sample statistics are reported in the abstract. The authors present an amino acid-centric model to explain glucagon-mediated energy expenditure and review the implications of glucagon-stimulated hypoaminoacidemia in the development of multi-agonist weight-loss therapies.
Why it matters
Clarifying the metabolic pathways mediating glucagon-driven energy expenditure helps refine next-generation multi-agonist anti-obesity drugs to maximize weight loss while monitoring potential metabolic consequences like amino acid depletion.
Limits
The abstract contains no original experimental data, quantitative outcomes, or systematic literature search methodology. Much of the evidence relies on preclinical rodent models, and the exact mechanisms in humans remain incompletely defined.
Cited by
- context Dietary protein stimulates the secretion of glucagon, an opposing hormone to insulin that aids in weight loss.